Inovalon Holdings Inc. (INOV) Trading Down 2.4%
Inovalon Holdings Inc. (NASDAQ:INOV) shares dropped 2.4% during mid-day trading on Tuesday . The stock traded as low as $18.19 and last traded at $18.32, with a volume of 176,330 shares traded. The stock had previously closed at $18.77.
A number of research analysts have issued reports on the stock. Robert W. Baird downgraded shares of Inovalon Holdings from an “outperform” rating to a “neutral” rating and cut their target price for the company from $22.00 to $21.00 in a research report on Thursday, April 21st. Morgan Stanley downgraded shares of Inovalon Holdings from an “equal weight” rating to an “underweight” rating and set a $16.00 target price on the stock. in a research report on Wednesday, March 30th. TheStreet upgraded shares of Inovalon Holdings from a “sell” rating to a “hold” rating in a research report on Monday, July 18th. KeyCorp restated a “buy” rating and set a $26.00 target price on shares of Inovalon Holdings in a research report on Sunday, May 22nd. Finally, Pacific Crest assumed coverage on shares of Inovalon Holdings in a research report on Tuesday, March 29th. They set an “overweight” rating and a $26.00 target price on the stock. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and five have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $21.71.
The stock has a market cap of $2.78 billion and a price-to-earnings ratio of 49.95. The firm’s 50 day moving average price is $18.23 and its 200 day moving average price is $17.96.
Inovalon Holdings (NASDAQ:INOV) last announced its quarterly earnings data on Wednesday, May 4th. The company reported $0.05 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.08 by $0.03. The business earned $102.70 million during the quarter, compared to analysts’ expectations of $97.96 million. During the same period in the previous year, the business earned $0.11 EPS. Inovalon Holdings’s revenue for the quarter was up 9.7% on a year-over-year basis. Analysts predict that Inovalon Holdings Inc. will post $0.56 earnings per share for the current fiscal year.
In other Inovalon Holdings news, insider Daniel L. Rizzo sold 43,577 shares of the company’s stock in a transaction on Tuesday, July 12th. The stock was sold at an average price of $20.02, for a total value of $872,411.54. Following the completion of the transaction, the insider now owns 320,385 shares in the company, valued at approximately $6,414,107.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Keith R. Dunleavy acquired 30,000 shares of Inovalon Holdings stock in a transaction on Monday, May 9th. The stock was acquired at an average price of $16.68 per share, with a total value of $500,400.00. Following the purchase, the chief executive officer now directly owns 53,147 shares in the company, valued at $886,491.96. The disclosure for this purchase can be found here.
A number of hedge funds and institutional investors have made changes to their positions in the stock. Russell Frank Co increased its position in shares of Inovalon Holdings by 29.1% in the fourth quarter. Russell Frank Co now owns 237,767 shares of the company’s stock worth $4,094,000 after buying an additional 53,651 shares during the period. Schroder Investment Management Group increased its position in shares of Inovalon Holdings by 384.4% in the fourth quarter. Schroder Investment Management Group now owns 223,800 shares of the company’s stock worth $3,805,000 after buying an additional 177,600 shares during the period. Finally, Eaton Vance Management acquired a new position in shares of Inovalon Holdings during the fourth quarter worth about $4,908,000.
Inovalon Holdings, Inc is a technology company. The Company combines advanced cloud-based data analytics and data-driven intervention platforms to provide services for health plans, hospitals, physicians, patients, pharmaceutical companies and researchers. Through its datasets, integration technologies, predictive analytics and subject matter expertise, the Company delivers platforms.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.